________________________________________________________________________________________________________________________________

(C) Algeta 2009 - Gillies O'Bryan-TearGillies O’Bryan-Tear to provide leadership
for Algeta’s phase III trial

August 2009. The appointment ends a difficult period for Algeta.

 

 

 

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 1page

Full Company License enquire here

Back to section

Related Editorial Articles

Transition: Cancer Research Translation
Christof von Kalle, Head of Germany’s National Center for Tumor Diseases on transitions in translational cancer research

Merck Serono on stem cell research: Clear away complete confusion of terms
Bernhard Kirschbaum, at the time Head of Global Research and Early Development for Merck Serono on stem cell research

Horizon Discovery: Mitigating risks and developing the U.S. business

Bayer AG: New Stakes in Stem Cells
Andreas Busch, responsible for Global Drug Discovery of Bayer AG offers insights for technology as well as business developers and venture capital